Exploring the Application of Bifunctional Metal Chelators in Treating Triple-Negative Breast Cancer

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Chemistry

Background:

• Triple-negative breast cancer (TNBC) lacks targeted therapies.
• Radiopharmaceuticals offer targeted treatment potential.
• Novel chelating agents are needed for effective radiolabeling.

Purpose of the Study:

• To synthesize and evaluate a novel bidentate bifunctional chelating agent, Lutetium-177-3,4-HOPO-Cetuximab (177Lu-3,4-HOPO-Cetuximab).
• To assess its in vitro and in vivo targeted killing ability against TNBC cells.

Main Methods:

• Synthesized 3,4-HOPO and coupled it with Cetuximab labeled with Lutetium-177 (177Lu).
• Evaluated cell viability and binding rates using CCK-8 and cell-binding assays.
• Assessed in vivo efficacy in a TNBC mouse model, monitoring tumor growth, body weight, and radioactivity distribution.

Main Results:

• 177Lu-3,4-HOPO-Cetuximab demonstrated significant dose-dependent cancer cell death and logarithmic cell binding.
• In vivo studies showed comparable tumor inhibition rates (approx. 37-38%) and no significant body weight changes compared to 177Lu-DOTA-Cetuximab.
• Histological analysis confirmed tumor cell necrosis following treatment.

Conclusions:

• 177Lu-3,4-HOPO-Cetuximab exhibits targeted therapeutic potential for triple-negative breast cancer.
• This agent is a promising candidate for targeted nuclear medicine treatment of TNBC.